ClinicalTrials.gg
SuspendedNCT03777579Updated Aug 8, 2019

A Study of First-line JS001 and Nab-paclitaxel Versus Palcelbo and Nab-Paclitaxel in Participants With Advanced Recurrent or Metastatic TNBC

A Phase 3 interventional study of JS001,an engineered anti-PD-1 antibody and Nab-Paclitaxel in Triple Negative Breast Cancer, sponsored by CSPC ZhongQi Pharmaceutical Technology Co., Ltd.. Suspended at 1 site in China. Open to female participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2019-08-08.

Sponsored by CSPC ZhongQi Pharmaceutical Technology Co., Ltd. (part of CSPC Pharmaceutical Group Limited) · Phase 3, Interventional, and Treatment

Why this study was suspended
trial handovered to another sponser.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
375
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 252 studies in Triple Negative Breast Neoplasms with a site in China — 126 open to participants now, 153 under way, 33 of them phase 3. Triple Negative Breast Neoplasms · China.

Planned enrollment
41st of 235
375 · median 90
Started
2018
with 11 others
Phase 3
48 of 252
19 open now
Registered
42nd of 252
by date

Among the 252 studies in Triple Negative Breast Neoplasms with a site in China, this one is the 41st largest by planned enrollment of the 235 interventional ones that give a count, is one of 12 that started in 2018, is one of 48 in phase 3, and was the 42nd registered.

Triple Negative Breast Neoplasms

1,219 studies on the registry are indexed under Triple Negative Breast Neoplasms; 445 are open to participants now.

Browse Triple Negative Breast Neoplasms studies →

Open to participants now

126 of the 252 studies in Triple Negative Breast Neoplasms with a site in China are open now. Recruiting first, the newest first:

121 more — sign in →

All 126 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 332 Triple Negative Breast Neoplasms studies recruiting now, 232 (70%) set no upper age limit and 85 (26%) stop at 75 or younger; 12 take children under 18; 6 take healthy volunteers.

This study: 18 Years to 70 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 252 studies in Triple Negative Breast Neoplasms with a site in China, or all of them as a file.
02

Study summary

This multicenter, randomized, double-blind study will evaluate the efficacy, safety of JS001 administered with nab-paclitaxel compared with placebo in combination with nab-paclitaxel as first-line therapy in participants with primarily diagnosed stage IV and recurrent or metastatic triple-negative breast cancer (TNBC) who have not received prior systemic therapy for metastatic breast cancer (mBC).

03

Conditions studied

  • Triple Negative Breast Cancer
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Primarily diagnosed stage IV or recurrent and , documented TNBC characterized by absence of human epidermal growth factor 2 (), estrogen receptor (ER), and progesterone receptor (PR) expression;
  2. No prior chemotherapy or targeted systemic therapy for inoperable stage IV or metastatic TNBC;
  3. Eligible for taxane monotherapy;
  4. performance status of 0 or 1;
  5. as defined by v1.1;
  6. Adequate hematologic and end-organ function。

Exclusion criteria

Exclusion Criteria:

  1. Known central nervous system (CNS) disease with active syndrome or untreated disease, except for treated asymptomatic ;
  2. History of disease;
  3. History of Anaphylaxis to PD-(L)1 antibody or antibody or paclitaxel;
  4. Prior allogeneic stem cell or solid organ transplantation;
  5. Active or ;
  6. Positive of antibody.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
375 participants (estimated)

Study arms

  • Experimental
    JS001 Plus Nab-Paclitaxel

    Participants assigned to JS001 plus nab-paclitaxel will receive both agents until disease progression or unacceptable toxicity.

    Drug: JS001,an engineered anti-PD-1 antibody · Drug: Nab-Paclitaxel

  • Placebo comparator
    Placebo Plus Nab-Paclitaxel

    Participants assigned to placebo plus nab-paclitaxel will receive both agents until disease progression or unacceptable toxicity.

    Drug: Nab-Paclitaxel · Drug: Placebo

Interventions

  • DrugJS001,an engineered anti-PD-1 antibody

    JS001 at a fixed dose of 240 milligrams via intravenous (IV) infusion on Days 1 of each 21-day cycle until disease progression or unacceptable toxicity.

    Also known as: Terepril monoclonal antibody

  • Nab-Paclitaxel at a starting dose of 125mg per square meter via IV infusion on Days 1, 8 of each 21-day cycle. Nab-Paclitaxel will be administered until disease progression or unacceptable toxicity.

    Also known as: Paclitaxel For Injection(Albumin Bound)

  • DrugPlacebo

    Placebo administered via intravenous (IV) infusion on Days 1 of each 21-day cycle until disease progression or unacceptable toxicity.

06

What researchers measure

Primary outcomes

  1. Progression-Free Survival (PFS) Assessed Using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1)by Independent Review Committee (IRC)

    PFS is defined as the time from randomization to the first occurrence of PD, as determined by the investigator using RECIST v1.1, or death from any cause during the study, whichever occurs first. PD is defined as greater than or equal to (\>/=) 20 percent (%) relative increase and \>/=5 millimeter (mm) of absolute increase in the sum of diameters (SD) of target lesions (TLs), taking as reference the smallest SD recorded since treatment started, or appearance of 1 or more new lesions.

    Time frame: From Day 1 to disease progression (PD) or death from any cause, assessed up to end of study (up to approximately 30 months)

Secondary outcomes

  1. Progression-Free Survival (PFS) Assessed Using RECIST v1.1 by investigator

    PFS is defined as the time from randomization to the first occurrence of PD, as determined by the investigator using RECIST v1.1, or death from any cause during the study, whichever occurs first. PD is defined as greater than or equal to (\>/=) 20 percent (%) relative increase and \>/=5 millimeter (mm) of absolute increase in the sum of diameters (SD) of target lesions (TLs), taking as reference the smallest SD recorded since treatment started, or appearance of 1 or more new lesions.

    Time frame: From Day 1 to PD or death from any cause, assessed up to end of study (up to approximately 30 months)

  2. Objective response rate (ORR) Assessed Using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1)by IRC

    ORR is defined as the rate of CR or PR, as determined by IRC using RECIST v1.1 criteria.

    Time frame: From Day 1 to PD or death from any cause, assessed up to end of study (up to approximately 30 months)

  3. Duration of response (DoR) Assessed Using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1)by IRC

    DoR is defined as the time period from the date of initial CR or PR until the date of PD or death from any cause, whichever occurs first.

    Time frame: From Day 1 to PD or death from any cause, assessed up to end of study (up to approximately 30 months)

  4. Disease control rate (DCR) Assessed Using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1)by IRC

    DCR is defined as the rate of of CR, PR, or stable disease according to RECIST v1.1.

    Time frame: From Day 1 to PD or death from any cause, assessed up to end of study (up to approximately 30 months)

  5. Overall Survival (OS)

    OS is defined as the time from randomization to death from any cause.

    Time frame: From Day 1 to death from any cause, assessed up to end of study (up to approximately 30 months)

  6. OS rate at 12 months

    OS is defined as the time from randomization to death from any cause.

    Time frame: the percent of participants that are alive at 12months from Day 1.

  7. OS rate at 24 months

    OS is defined as the time from randomization to death from any cause.

    Time frame: the percent of participants that are alive at 24 months from Day 1.

  8. PFS Assessed Using immune-related Response Evaluation Criteria in Solid Tumors (iRECIST) by investigator

    Progression is confirmed in the target lesion category if the next imaging assessment after iUPD (4-8 weeks later) confirms a further increase in sum of measures of target disease from iUPD, with an increase of at least 5mm.

    Time frame: From Day 1 to death from any cause, assessed up to end of study (up to approximately 30 months)

  9. ORR Assessed Using immune-related Response Evaluation Criteria in Solid Tumors (iRECIST) by investigator

    ORR is defined as the rate of iCR or iPR, as determined by investigator using iRECIST criteria.

    Time frame: From Day 1 to death from any cause, assessed up to end of study (up to approximately 30 months)

  10. DoR Assessed Using immune-related Response Evaluation Criteria in Solid Tumors (iRECIST) by investigator

    DoR is defined as the time period from the date of initial iCR or iPR until the date of iCPD or death from any cause, whichever occurs first.

    Time frame: From Day 1 to death from any cause, assessed up to end of study (up to approximately 30 months)

  11. DCR Assessed Using immune-related Response Evaluation Criteria in Solid Tumors (iRECIST) by investigator

    DCR is defined as the rate of of iCR, iPR, or stable disease according to iRECIST.

    Time frame: From Day 1 to death from any cause, assessed up to end of study (up to approximately 30 months)

  12. Percentage and severity of Participants With Adverse Events (AEs)

    percentage and CTC AE(v5.0) of AEs

    Time frame: From Day 1 to 60 days after last dose of study drug, assessed up to end of study (up to approximately 30 months)

  13. Percentage of Participants With Anti-Drug Antibodies (ATAs)

    Time frame: Pre-dose (60minutes±10minutes) on Day 1 of Cycles 1, 3, 5, 7, 9 and at every 6 cycles thereafter until disease progression, at disease progression. (maximum up to 30 months) (1 Cycle = 21 days)

07

Study locations

1 site
  • The fifth medical center of PLA general hospital
    Beijing, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Dec 2018 (actual). Primary completion is estimated for Dec 2019, 12 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 12, 2018
First posted
Dec 17, 2018
StartActual
Dec 21, 2018
Primary completionEst.
Dec 30, 2019
CompletionEst.
Jul 30, 2020
Last update
Aug 8, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 8, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03777579
Responsible party
Sponsor
First posted
Dec 17, 2018
Start date
Dec 21, 2018
Primary completion
Dec 30, 2019 (estimated)
Completion
Jul 30, 2020 (estimated)
Last update
Aug 8, 2019

Study contacts

JIANG ZE FEI, PHD
principal investigator · Beijing 302 Hospital

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is suspended, as verified in Dec 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion